H.C. Wainwright Maintains Coherus BioSciences(CHRS.US) With Buy Rating, Maintains Target Price $7

Moomoo NewsApr 30 01:33 ET · Ratings

Express News | HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

BenzingaApr 29 06:45 ET

Promising Clinical Data and Strategic Expansion Justify Buy Rating for Coherus Biosciences

TipRanksApr 29 06:15 ET · Ratings

Coherus BioSciences Reports Promising Clinical Data for CHS-114 Combined With Toripalimab in HNSCC and Gastric Cancer

Quiver QuantitativeApr 28 10:20 ET

Coherus Biosciences: Data From Ongoing Phase 1 Clinical Trial Evaluating CHS-114 Shows Clinical Efficacy And Proof Of Mechanism In HNSCC In Combination With Toripalimab

BenzingaApr 28 10:12 ET

Coherus Presents Promising Early Clinical Data From Phase 1 Dose Expansion Study of CHS-114 in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at AACR 2025

GlobeNewswireApr 28 10:10 ET